Core Viewpoint - International Medical (000516) is focusing on enhancing its medical expertise and technology while addressing investor concerns regarding its financial performance and market perception [2][3][4]. Group 1: Company Performance and Financials - As of October 13, 2025, International Medical's stock closed at 4.98 yuan, up 2.26%, with a turnover rate of 1.62% and a trading volume of 356,400 shares, amounting to a transaction value of 176 million yuan [1]. - The company reported a negative net profit of 286.9 million yuan for 2024, 499 million yuan for 2023, and 1.123 billion yuan for 2022, raising concerns about its ongoing financial viability [3][4]. Group 2: Medical Expertise and Technology - The company emphasizes a patient-centered approach, with over 29.2% of its medical staff holding senior technical titles and 39.2% having master's or doctoral degrees [2]. - International Medical is developing its AI capabilities, focusing on "intelligent clinical assistance" to enhance healthcare efficiency, with ongoing internal trials for smart services [2][4]. Group 3: Strategic Partnerships and Internationalization - The company is committed to deepening collaborations with internationally renowned medical institutions to bolster its internationalization strategy [3]. - There are inquiries about potential partnerships with top hospitals, such as the Mary Hospital in Hong Kong, to enhance medical skills and services [2][3]. Group 4: Market Sentiment and Investor Relations - On October 13, 2025, the net inflow of main funds into the stock was 20.51 million yuan, indicating positive engagement from major investors, despite a net outflow from retail investors [4]. - The company acknowledges the fluctuating financing balance as a reflection of market sentiment and encourages investors to focus on its long-term strategic developments [4].